Development of less-intensive treatment for HPV-associated head and neck cancer.

• Project/Area Number: 24592597
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Kagawa University
• Principal Investigator: HOSHIKAWA Hirohi 香川大学, 医学部, 准教授 (70294767)
• Co-Investigator(Kenkyū-buntansha): 岸野 毅日人 香川大学, 医学部附属病院, 助教 (20532683)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: papillpmavirus / head and neck / p16 / prognosis / radiosensitivity / drugsensitivity / HPV / 放射線感受性 / p53

Outline of Final Research Achievements

It is known that the incidence of head and neck squamous cell carcinoma (HNSCC) associated with papillomavirus (HPV) infection has increased over the past decades. Evidence from retrospective case series suggests improved prognosis in patients with HPV-positive HNSCC, thus the development of less-intensive treatment is expected. Although overall survival in patients with HPV-positive was better than that with HPV-negative tumors, no significant difference was observed. In this study, we could not show the difference of sensitivity to radiation and anti-cancer drug according to HPV status using collagen gel droplet embedded culture drug sensitivity test (CD-DST).